Toggle light / dark theme

Rejuvenation Biotechnology: on track to be the biggest industry ever.

Dr Aubrey de Grey, CSO at the SENS Research Foundation speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Aubrey discusses Rejuvenation biotechnology and how it’s on track to become the biggest industry ever.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.
Read our latest magazine at www.masterinvestor.co.uk/magazine
Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz
Keep in touch:
Newsletter | https://masterinvestor.co.uk/subscribe
Twitter | https://twitter.com/masterinvestor
Facebook | https://facebook.com/masterinvestor
LinkedIn | https://www.linkedin.com/company/masterinvestor

One of the most vexing questions many of us face once we hit our 60s is: Where should we live as we get older? I’m not talking about those “Best Places to Live” rankings. I mean what kind of home, and type of community, would be most suitable. That’s why I was eager to hear what several gerontologists had to say in their session at last week’s Gerontological Society of America conference about how they decided where they’d live in later life.


What kind of home and community is most suitable? The answer isn’t always rational.

Gene therapies to reverse immunosenescence and atherosclerosis.

CEO of Repair Biotechnologies speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Reason discusses gene therapies to reverse immunosenescence and atherosclerosis.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.

Read our latest magazine at www.masterinvestor.co.uk/magazine

New post!


Having a faster rate of epigenetic aging, as measured by the epigenetic age metric, AgeAccelGrim, is associated with a significantly increased risk of death for all causes in a variety of cohorts, including the Framingham Heart Study (FHS), the Women’s Health Initiative (WHI) study, the InChianti study, the Jackson Heart Study (JHS), and collectively, when evaluated as a meta-analysis (Lu et al. 2019):

Screen Shot 2019-12-07 at 2.23.27 PM.png

With the goal of minimizing disease risk and maximizing longevity, can epigenetic aging be slowed? Shown below is the correlation between dietary components with AgeAccelGrim. Dietary factors that were significantly associated (the column labelled, “p”) with a younger epigenetic age were carbohydrate intake, dairy, whole grains, fruit, and vegetables. In contrast, dietary fat intake and red meat were associated with older epigenetic ages (Lu et al. 2019):

Families with long, healthy life spans focus of $68 million grant~ via Washington University School of Medicine in St. Louis https://medicine.wustl.edu/news/families-with-long-healthy-l…ion-grant/


A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

Ethical concerns about new and emerging technologies that could significantly extend human lifespans generally focus on their potential impact on individuals and the permissibility of providing such treatment options. Because these technologies might also prompt us to assess and balance interests of different individuals and groups, given resource and production limitations, life-extension technologies provoke profound conversations about the nature and value of traditional conceptions of humanity.


Life extension requires careful consideration of resource scarcity, justice, and what, if anything, is intrinsic to the experiences we define as human.